Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Atrial Flutter, Atrial Fibrillation, and Ischemic Stroke
    STROKE ALERT

    Atrial Flutter, Atrial Fibrillation, and Ischemic Stroke

    September 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Atrial Fibrillation After Radiofrequency Ablation of Type I Atrial Flutter

    After Ischemic Stroke Related to Atrial Fibrillation, Direct Oral Anticoagulants Are Superior to Vitamin K Antagonists

    Anticoagulation in Patients with Ischemic Stroke Related to Atrial Fibrillation, Following Reperfusion Therapy

    Related Products

    Cryptogenic Stroke and Atrial Fibrillation

    Pattern of Atrial Fibrillation Is Associated with Outcomes After Stroke

    Keywords

    stroke

    atrial

    cha2ds2-vasc

    By Matthew E. Fink, MD

    Professor and Chairman, Department of Neurology, Weill Cornell Medical College; Neurologist-in-Chief, New York Presbyterian Hospital

    Dr. Fink reports he is a retained consultant for Procter & Gamble and Pfizer.

    SOURCE: Lin YS, Chen YL, Chen TS, et al. Comparison of clinical outcomes among patients with atrial fibrillation or atrial flutter stratified by CHA2DS2-VASc score. JAMA Network Open 2018;1:e180941. doi:10.1001/jamanetworkopen.2018.0941.

    Atrial flutter (AFL) and atrial fibrillation (AF) often are grouped together in terms of risk stratification for ischemic stroke. Risk and decisions regarding institution of antithrombotic therapy have relied heavily on the use of a scoring system known as CHADS. The CHA2DS2-VASc scoring system was developed in 2010 and calculates according to a point system (possible score range, 0-9) in which two points are assigned for history of stroke/transient ischemic attack and age > 75 years; one point is assigned for age 65-74 years, a history of congestive heart failure, hypertension, diabetes, vascular disease, and female sex. A high score indicates an increased risk of ischemic stroke and often results in treatment with antithrombotic therapy. However, it is uncertain if risks in patients with AFL are similar to the risks in patients with AF. Lin et al conducted this study to analyze the incidence of ischemic stroke, hospitalization for heart failure, and all-cause mortality as it relates to the calculation of the CHADS score comparing patients with AF and AFL.

    Data were analyzed from a nationwide database of the Taiwan National Health Insurance Research Database with information collected from 1997 through 2012, encompassing 23 million Taiwan residents. Patients with AF and AFL were paired with age- and sex-matched controls. There were 188,811 patients in the AF cohort and 6,121 patients in the AFL cohort, with 24,484 patients in the matched-control cohort. The patients with AF tended to be older, were more predominantly female, and had higher CHA2DS2-VASc scores than the patients with AFL and control participants. After stratification by CHA2DS2-VASc score, the incidence of ischemic stroke, heart failure hospitalization, and all-cause mortality were significantly higher in the AF cohort than in the matched-control cohort. In comparing the AFL cohort to matched controls, the incidences of heart failure and all-cause mortality were significantly higher, but ischemic stroke was higher only in patients who had a CHA2DS2-VASc score of 5 to 9. In the AF cohort, the incidence of ischemic stroke was significantly higher at a CHA2DS2-VASc score of 1 or higher. The authors of this well-designed study found significantly different clinical outcomes between patients with AFL and AF, and the significance of the CHA2DS2-VASc score in predicting stroke may be different when applied to AFL patients vs. AF patients.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 38, No. 1) - September 2018
    September 1, 2018

    Table Of Contents

    Which Is Better for Nonconvulsive Seizures: Lacosamide or Fosphenytoin?

    Initial Management of Patients With Medication-overuse Headache

    Unilateral Scapular Winging

    Hypercapnic Acidosis and Clinical Outcomes in Patients With Acute Brain Injury

    Recanalization Treatment in Pediatric Arterial Ischemic Stroke

    Atrial Flutter, Atrial Fibrillation, and Ischemic Stroke

    Dual Antiplatelet Therapy for Acute Ischemic Stroke and TIA

    Treatment of Chronic Subdural Hematoma With Atorvastatin

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing